The Safety and Efficacy of Pemetrexed Rechallenge With Bevacizumab for Patients With Advanced Non-squamous Non-small Cell Lung Cancer
Phase of Trial: Phase II
Latest Information Update: 16 Aug 2019
Price : $35 *
At a glance
- Drugs Bevacizumab (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 12 Aug 2019 Status changed from recruiting to discontinued.
- 05 Mar 2018 Planned End Date changed from 1 Jul 2017 to 1 Mar 2019.
- 22 Feb 2016 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.